Key result
Margatoxin, a novel peptide from scorpion venom, selectively inhibits the Kv1.3 channel of human T-lymphocytes with 20-fold greater potency than charybdotoxin (half-block at ~50 pM).
Why the study?
Does margatoxin selectively inhibit Kv1.3 channels compared to charybdotoxin?
Does margatoxin selectively inhibit Kv1.3 channels compared to charybdotoxin?
Effect estimate: 20-fold more potent
Margatoxin is a highly potent and selective inhibitor of Kv1.3 channels, making it a valuable tool for studying their physiological role.
No takes yet. Share an insight, caveat, or question.
Margatoxin supplies a potent Kv1.3 probe for T-lymphocyte research; leaves open any clinical translation in immune disorders.
García‐Calvo et al. (1993) studied Kv1.3 channel inhibition. Margatoxin (MgTX) vs. Charybdotoxin (ChTX) was evaluated on Inhibition of Kv1.3 channel (n-type current of human T-lymphocytes) (20-fold more potent). Margatoxin, a novel peptide from scorpion venom, selectively inhibits the Kv1.3 channel of human T-lymphocytes with 20-fold greater potency than charybdotoxin (half-block at ~50 pM).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: